Clinical Trial News and Research

RSS

Overgrowth of bacteria in the gut linked to IBS

An overgrowth of bacteria in the gut has been definitively linked to Irritable Bowel Syndrome in the results of a new Cedars-Sinai study which used cultures from the small intestine. This is the first study to use this "gold standard" method of connecting bacteria to the cause of the disease that affects an estimated 30 million people in the United States.

28 May 2012

City of Hope receives CIRM grant to develop T cell-based immunotherapy against glioma

City of Hope was granted a $5,217,004 early translational research award by the California Institute for Regenerative Medicine (CIRM) to support the development of a T cell-based immunotherapy that re-directs a patient's own immune response against glioma stem cells.

28 May 2012

UCLA Face Transplantation Program seeks candidates for clinical trial

The UCLA Health System has launched the UCLA Face Transplantation Program, the first surgical program of its kind in the western United States and one of only a handful in the nation.

25 May 2012

Bacteria are key contributors to the cause of IBS, study confirms

25 May 2012

Merck welcomes launch of ROTATEQ in Rwanda of Africa’s rotavirus vaccination program

Merck, known as MSD outside the United States and Canada, welcomes today's launch in Rwanda of Africa's first national rotavirus vaccination program with ROTATEQ (rotavirus vaccine, live, oral, pentavalent), Merck's vaccine for the prevention of rotavirus disease.

25 May 2012

Gene therapy can effectively treat ADA-deficient severe combined immunodeficiency

Severe combined immunodeficiency is defect in the immune system that results in a loss of the adaptive immune cells known as B cells and T cells. Mutations in several different genes can lead to the development of severe combined immunodeficiency, including mutation of the adenosine deaminase (ADA) gene. Traditional treatment options, such as enzyme replacement therapy, are of limited efficacy, but bone marrow transplant from a compatible donor leads to a better response.

25 May 2012

Insmed initiates patient screening for ARIKACE phase 2 NTM lung disease trial

Insmed Incorporated, a biopharmaceutical company, today announced that it has begun screening patients for its U.S. phase 2 clinical trial, Treatment with ARIKACE to Realize Greater Efficacy Trial (TARGET-NTM), of ARIKACE (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacterial (NTM) lung disease.

24 May 2012

Optogenetic Therapies for Vision workshop to be held on June 1

The Foundation Fighting Blindness and Massachusetts Eye and Ear will host the Optogenetic Therapies for Vision workshop on Friday, June 1, from 8 a.m.-6 p.m., in Boston.

24 May 2012

Nevro to initiate Senza HF-SCS System study for chronic pain

Nevro Corp., a medical device company focused on achieving improved pain relief for patients suffering from debilitating chronic pain, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for initiation of its SENZA-RCT study, a U.S. prospective, randomized, controlled pivotal clinical trial evaluating the safety and efficacy of Nevro's high-frequency spinal cord stimulation system for the treatment of chronic pain.

24 May 2012

Zytoprotec completes PD-protec Phase I/II trial on kidney failure

Zytoprotec, a company developing drugs based on active cytoprotection, today announced the completion of a Phase I/II clinical trial with its lead product, PD-protec.

24 May 2012

Phase I/II clinical trial of novel dialysate completed by Zytoprotec

Zytoprotec, a company developing drugs based on active cytoprotection, today announced the completion of a Phase I/II clinical trial with its lead product, PD-protec™. The product is developed to improve the treatment of patients with kidney failure.

23 May 2012

Scientists may be step closer to developing new therapy for AML

Scientists at Virginia Commonwealth University Massey Cancer Center may be one step closer to developing a new therapy for acute myeloid leukemia (AML) after discovering that the targeted agents obatoclax and sorafenib kill leukemia cells much more effectively when combined than when the drugs are administered individually.

23 May 2012

Researchers to initiate Crenezumab clinical trial to treat Alzheimer's

After an announcement by federal officials approving clinical trials for the drug Crenezumab, researchers searching for a way to treat Alzheimer's Disease are gearing up for a rare study that will allow them to test a therapy for a genetically predestined disease -- before its onset.

23 May 2012

New clinical trial to evaluate HSP90 inhibitor plus hormonal therapy for breast cancer

Pushed to the brink of survival, the hyper-driven cells of a cancerous tumor tap into an ancient system that has helped organisms cope with internal stresses and environmental challenges since life began. As an integral part of this system, heat shock protein 90 (HSP90) has been shown to help malignant cells accommodate the genetic changes and profound disturbances in normal biology that occur in cancers.

23 May 2012

HVTN opens enrollment in GeoVax’s GM-CSF adjuvanted vaccine Phase 1 trial for HIV

GeoVax Labs, Inc., an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced that the NIH-funded HIV Vaccine Trials Network (HVTN) has opened enrollment for a Phase 1 trial for the company's second-generation HIV vaccine.

23 May 2012

Results from Boehringer Ingelheim’s Respimat Phase II study on moderate, persistent asthma

Boehringer Ingelheim announced today results from a Phase II study evaluating the investigational compound tiotropium delivered once-daily via the Respimat Inhaler in adolescents with symptomatic, moderate persistent asthma.

23 May 2012

IACs may increase risk of arrhythmias in young individuals with asthma

Use of inhaled anticholinergics (IACs) has been associated with an increased risk of potentially dangerous heart arrhythmias among young asthma patients, according to a study conducted by researchers at the University of Illinois at Chicago.

23 May 2012

Data from Alvine’s ALV003 Phase 2A trial on celiac disease presented at DDW 2012

Alvine Pharmaceuticals, Inc. today announced the presentation of data from a Phase 2A trial of its lead compound, ALV003, at the 2012 Digestive Diseases Week (DDW) meeting held in San Diego, California. The study results met the primary endpoint of demonstrating that oral ALV003, administered in the context of a gluten free diet (GFD), can diminish gluten-induced intestinal mucosal injury in well-controlled celiac disease patients. The company plans to initiate a Phase 2B trial later this year.

23 May 2012

Diamyd Medical completes enrollment in NP2 Enkephalin Phase II study for cancer pain

The last study participant has been recruited to Diamyd Medical's Phase II study in which cancer pain is treated with the drug candidate NP2 Enkephalin. The study is thus fully enrolled and results are expected to be reported in five to seven weeks.

22 May 2012

New research reveals effective treatments for gastrointestinal conditions

New research being presented at Digestive Disease Week- (DDW) reveals effective treatments for a number of gastrointestinal conditions, which are often chronic and costly.

22 May 2012

Clinical Trial News and Research

Overgrowth of bacteria in the gut linked to IBS

City of Hope receives CIRM grant to develop T cell-based immunotherapy against glioma

UCLA Face Transplantation Program seeks candidates for clinical trial

Bacteria are key contributors to the cause of IBS, study confirms

Merck welcomes launch of ROTATEQ in Rwanda of Africa’s rotavirus vaccination program

Gene therapy can effectively treat ADA-deficient severe combined immunodeficiency

Insmed initiates patient screening for ARIKACE phase 2 NTM lung disease trial

Optogenetic Therapies for Vision workshop to be held on June 1

Nevro to initiate Senza HF-SCS System study for chronic pain

Zytoprotec completes PD-protec Phase I/II trial on kidney failure

Phase I/II clinical trial of novel dialysate completed by Zytoprotec

Scientists may be step closer to developing new therapy for AML

Researchers to initiate Crenezumab clinical trial to treat Alzheimer's

New clinical trial to evaluate HSP90 inhibitor plus hormonal therapy for breast cancer

HVTN opens enrollment in GeoVax’s GM-CSF adjuvanted vaccine Phase 1 trial for HIV

Results from Boehringer Ingelheim’s Respimat Phase II study on moderate, persistent asthma

IACs may increase risk of arrhythmias in young individuals with asthma

Data from Alvine’s ALV003 Phase 2A trial on celiac disease presented at DDW 2012

Diamyd Medical completes enrollment in NP2 Enkephalin Phase II study for cancer pain

New research reveals effective treatments for gastrointestinal conditions

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer